ENTACAPONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H15N3O5
Molecular Weight	305.286
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C(=C1)[N+]([O-])=O

InChI

InChIKey=JRURYQJSLYLRLN-BJMVGYQFSA-N

InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+

HIDE SMILES / InChI

Molecular Formula	C14H15N3O5
Molecular Weight	305.286
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00494
Curator's Comment: Description was created based on several sources, including http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000171/WC500033075.pdf

Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor. The mechanism of action of entacapone is believed to be through its ability to inhibit COMT in peripheral tissues, altering the plasma pharmacokinetics of levodopa. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to a greater reduction in the manifestations of parkinsonian syndrome. Entacapone is used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Catechol O-methyltransferase 21 Target ID: CHEMBL2023 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9681662	Inhibitor 8504	151.0 nM [IC50]
NCI-H1299 3 Target ID: CHEMBL612255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24148818	Inhibitor 8504	76.8 µM [IC50]
Mycobacterium tuberculosis 21 Target ID: CHEMBL360 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19578428	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Parkinson's disease 232 Sources: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/comtan.pdf	Secondary		Approved 8583	Comtan Approved Use Comtan is indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with Parkinson’s disease Launch Date 1999

C_max

Value	Dose	Co-administered	Analyte	Population
1325 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 8 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1095 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 10 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020796s15lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2084 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 8 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1989 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 10 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 8 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10492060	200 mg 10 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA\|CARBIDOPA	LEVODOPA\|CARBIDOPA	ENTACAPONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020796s15lbl.pdf			ENTACAPONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
25 mg single, intravenous Dose: 25 mg Route: intravenous Route: single Dose: 25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8039535	healthy, 24 years (range: 22-28 years) Health Status: healthy Age Group: 24 years (range: 22-28 years) Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/8039535	Sources: https://pubmed.ncbi.nlm.nih.gov/8039535
2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Other AEs: Abdominal pain, Loose stools... Other AEs: Abdominal pain Loose stools Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Other AEs: Abdominal pain, Loose stools... Other AEs: Abdominal pain Loose stools Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
800 mg single, oral Highest studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Disc. AE: Psychiatric symptom, Diarrhea... AEs leading to discontinuation/dose reduction: Psychiatric symptom (2%) Diarrhea (2%) Dyskinesia (2%) Nausea (2%) Abdominal pain (1%) Hyperkinesia (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF

AEs

AE	Significance	Dose	Population
Abdominal pain		2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Loose stools		2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Abdominal pain		2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Loose stools		2400 mg 1 times / day steady, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: steady Dose: 2400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Abdominal pain	1% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Diarrhea	2% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Dyskinesia	2% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Hyperkinesia	2% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Nausea	2% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF
Psychiatric symptom	2% Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4798	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4798
ChemicalBook	CB5726435	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5726435
eMolecules	27345033	https://www.emolecules.com/cgi-bin/more?vid=27345033
MolPort	MolPort-003-847-054	https://www.molport.com/shop/molecule-link/MolPort-003-847-054
Selleck Chemicals	entacapone	http://www.selleckchem.com/products/entacapone.html
ZINC	ZINC000035342787	http://zinc15.docking.org/substances/ZINC000035342787

PubMed

Title	Date	PubMed
Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity.	2010-05-14	20150427
Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.	2010-04-22	20334432
Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.	2010-01	19783845
Mirtazapine-associated urinary retention.	2010	20686159
Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine.	2009-12-15	19890998
Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis.	2009-07	19578428
Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient.	2008-12-15	18814889
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.	2008-12	18722529
[Treatment of Parkinson's disease at present and in the future].	2008-11	19198095
Novel screening assay for antioxidant protection against peroxyl radical-induced loss of protein function.	2007-11	17705259
Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.	2007-01	17089403
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.	2006-05	16437585
Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.	2005-12-13	16344532
Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases.	2005-07	15802387
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005-06	15962942
Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase.	2004-12-02	15566291
Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.	2004-11	15502970
An active and water-soluble truncation mutant of the human UDP-glucuronosyltransferase 1A9.	2004-04	15044611
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.	2003-08	12898346
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.	2003-08	12876237
An artist's view of drug-induced hallucinosis.	2003-07	12815666
Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor.	2003-02	12588639
Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.	2003-02	12538800
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).	2002-04	11939936
Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.	2001-10-05	11586115
L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations.	2001-08	11498717
Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.	2001-06	11440283
Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.	2001	11244274
Entacapone.	2000-09	10981253
Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.	2000-06	10882160
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.	2000-03	10762340
Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.	1995-04-04	7703232
Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.	1995-02-14	7768276

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose of Comtan (entacapone) is one 200 mg tablet administered concomitantly with each levodopa and carbidopa dose to a maximum of 8 times daily (200 mg x 8 = 1,600 mg per day). Comtan should always be administered in association with levodopa and carbidopa. Entacapone has no antiparkinsonian effect of its own.

Route of Administration: Oral

In Vitro Use Guide

Kinetic assays indicate that Comtan inhibits InhA activity by 47.0% at an entacapone concentration of approximately 80 uM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:13:48 GMT 2025` Edited by `admin` on `Mon Mar 31 18:13:48 GMT 2025`
Record UNII	4975G9NM6T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

COMTAN

Preferred Name

English

ENTACAPONE

Official Name

English

OR-611

Code

English

Entacapone [WHO-DD]

Common Name

English

ENTACAPONE [EP MONOGRAPH]

Common Name

English

COMTESS

Brand Name

English

CORBILTA COMPONENT ENTACAPONE

Brand Name

English

ENTACAPONE [ORANGE BOOK]

Common Name

English

ENTACAPONE [JAN]

Common Name

English

ENTACAPONE [MI]

Common Name

English

ENTACAPONE [USP-RS]

Common Name

English

entacapone [INN]

Common Name

English

(E)-.ALPHA.-CYANO-N,N-DIETHYL-3,4-DIHYDROXY-5-NITROCINNAMAMIDE

Systematic Name

English

ENTACAPONE [MART.]

Common Name

English

LEVODOPA/CARBIDOPA/ENTACAPONE ORION COMPONENT ENTACAPONE

Brand Name

English

ENTACAPONE [EMA EPAR]

Common Name

English

ENTACAPONE [USP MONOGRAPH]

Common Name

English

STALEVO COMPONENT ENTACAPONE

Brand Name

English

ENTACAPONE [USAN]

Common Name

English

ENTACAPONE [VANDF]

Common Name

English

ENTACAPONE TEVA

Brand Name

English

ENTACAPONE ORION

Brand Name

English

2-PROPENAMIDE, 2-CYANO-3-(3,4-DIHYDROXY-5-NITROPHENYL)-N,N-DIETHYL-

Systematic Name

English

Classification Tree Code System Code

NDF-RT

N0000175756